信隆健康(002105) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥240,067,340.31, representing a decrease of 11.60% compared to ¥271,574,492.33 in the same period last year[4] - Net profit attributable to shareholders was ¥2,457,102.84, down 80.39% from ¥12,528,280.11 year-on-year[4] - Basic earnings per share decreased by 79.41% to ¥0.007 from ¥0.034 in the same period last year[4] - Net profit for Q1 2024 was CNY 2,719,974.07, a decline of 78.7% compared to CNY 12,781,217.11 in Q1 2023[23] - The company’s comprehensive income for Q1 2024 was CNY 2,784,326.79, down from CNY 10,516,920.06 in Q1 2023[23] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥19,205,552.16, a decline of 123.98% compared to ¥80,085,514.51 in the previous year[4] - Cash inflow from operating activities totaled CNY 247,087,594.13, down 36.67% from CNY 390,651,248.34 in the previous year[24] - Cash outflow from operating activities was CNY 266,293,146.29, a decrease of 14.23% compared to CNY 310,565,733.83 in the prior period[24] - Cash flow from investing activities was negative CNY 17,544,698.62, worsening from negative CNY 6,116,085.50 year-over-year[24] - The ending balance of cash and cash equivalents was CNY 475,835,215.24, down from CNY 520,000,880.37 at the end of the previous period[25] Assets and Liabilities - Total assets decreased by 5.19% to ¥1,687,798,810.11 from ¥1,780,277,597.94 at the end of the previous year[4] - Current liabilities totaled CNY 559,531,307.50, a decrease of 3.0% from CNY 576,536,955.53 in the previous year[20] - The company's total assets decreased to CNY 1,687,798,810.11 from CNY 1,695,760,524.19, reflecting a reduction of 0.5%[20] - The company's equity attributable to shareholders fell by 6.36% to ¥911,346,638.12 from ¥973,205,744.71 at the end of the previous year[4] Borrowings and Financing - The company reported a significant increase in short-term borrowings by 11.90%, rising to ¥230,562,590.21 from ¥206,039,226.83[7] - Cash inflow from financing activities was CNY 130,067,374.73, an increase of 12.93% from CNY 115,654,645.73 in the previous year[25] - Net cash flow from financing activities was positive CNY 12,903,073.91, a turnaround from negative CNY 55,801,251.73 in the same period last year[25] Research and Development - The company's R&D expenses increased slightly by 1.69% to ¥9,820,715.71 from ¥9,657,865.39 year-on-year[8] - Research and development expenses for Q1 2024 were CNY 9,820,715.71, slightly up from CNY 9,657,865.39 in Q1 2023[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 22,044, with the largest shareholder holding 41.97% of the shares[9] Performance Compensation - The company received a cash compensation of RMB 606.48 million from the original shareholders of Tian Teng Power Technology Co., Ltd. for not meeting performance commitments in 2019[13] - Tian Teng Power's net profit for 2020 was RMB -1,386.06 million, resulting in a compensation obligation of RMB 717.21 million due to unmet performance commitments[14] - The total performance compensation due from Tian Teng Power for 2020 and 2021 amounts to RMB 1,763.03 million[14] - The company has signed a pledge agreement to secure performance compensation from Tian Teng Power's original controlling shareholder[14] Other Financial Information - The company reported a financial expense of CNY -1,159,100.59, a significant improvement compared to CNY 8,529,838.66 in the previous year[23] - The company did not undergo an audit for the Q1 2024 report[26] - The report indicates that the company has not yet implemented the new accounting standards for the current year[26]